Nothing Special   »   [go: up one dir, main page]

FI20095269A - Human endothelial cell molecule affecting the binding of lymphocytes - Google Patents

Human endothelial cell molecule affecting the binding of lymphocytes Download PDF

Info

Publication number
FI20095269A
FI20095269A FI20095269A FI20095269A FI20095269A FI 20095269 A FI20095269 A FI 20095269A FI 20095269 A FI20095269 A FI 20095269A FI 20095269 A FI20095269 A FI 20095269A FI 20095269 A FI20095269 A FI 20095269A
Authority
FI
Finland
Prior art keywords
binding
vap
endothelial cell
lymphocytes
cell molecule
Prior art date
Application number
FI20095269A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI121176B (en
Inventor
Marko Salmi
Sirpa Jalkanen
Original Assignee
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25404388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20095269(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Corp filed Critical Biotie Therapies Corp
Publication of FI20095269A publication Critical patent/FI20095269A/en
Application granted granted Critical
Publication of FI121176B publication Critical patent/FI121176B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A novel endothelial cell molecule, VAP-1, that mediates lymphocyte binding in man, is described. Anti-VAP-1 monoclonal antibodies are described and the monoclonal antibody 1B2 is provided by this invention, as well as the hybridoma cell line (DSM ACC2041) which produces it. This invention further provides methods for the treatment of inflammatory and autoimmune diseases by the administration of VAP-1 binding compounds, such as anti-VAP-1 antibodies.
FI20095269A 1992-06-09 2009-03-16 Human endothelial cell molecule affecting the binding of lymphocytes FI121176B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89535492A 1992-06-09 1992-06-09
US89535492 1992-06-09
PCT/FI1993/000250 WO1993025582A1 (en) 1992-06-09 1993-06-09 A novel endothelial cell molecule mediating lymphocyte binding in man
FI9300250 1993-06-09

Publications (2)

Publication Number Publication Date
FI20095269A true FI20095269A (en) 2009-03-16
FI121176B FI121176B (en) 2010-08-13

Family

ID=25404388

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20095269A FI121176B (en) 1992-06-09 2009-03-16 Human endothelial cell molecule affecting the binding of lymphocytes

Country Status (14)

Country Link
EP (1) EP0656906B1 (en)
JP (2) JP3431922B2 (en)
KR (1) KR100268772B1 (en)
AT (1) ATE184315T1 (en)
AU (1) AU671837B2 (en)
CA (1) CA2137551C (en)
DE (1) DE69326347T2 (en)
DK (1) DK0656906T3 (en)
ES (1) ES2135480T3 (en)
FI (1) FI121176B (en)
GR (1) GR3031255T3 (en)
HU (1) HU217175B (en)
NZ (2) NZ299958A (en)
WO (1) WO1993025582A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0002234A3 (en) * 1997-05-23 2005-11-28 Biotie Therapies Ltd Vascular adhesion protein-1 having oxidase activity
FI20020807A0 (en) * 2002-04-29 2002-04-29 Biotie Therapies Oyj Novel humanized anti-VAP-1 monoclonal antibodies
FI20061156A0 (en) 2006-12-27 2006-12-27 Elina Kivi New peptides
FI20075278A0 (en) * 2007-04-20 2007-04-20 Biotie Therapies Corp Novel completely human anti-VAP-1 monoclonal antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6

Also Published As

Publication number Publication date
JP3431922B2 (en) 2003-07-28
GR3031255T3 (en) 1999-12-31
KR100268772B1 (en) 2000-10-16
HUT75824A (en) 1997-05-28
NZ253151A (en) 1997-03-24
CA2137551C (en) 2002-03-26
ES2135480T3 (en) 1999-11-01
DK0656906T3 (en) 1999-12-20
KR950701938A (en) 1995-05-17
JP3500384B2 (en) 2004-02-23
CA2137551A1 (en) 1993-12-23
HU217175B (en) 1999-12-28
AU671837B2 (en) 1996-09-12
FI121176B (en) 2010-08-13
ATE184315T1 (en) 1999-09-15
EP0656906B1 (en) 1999-09-08
DE69326347D1 (en) 1999-10-14
EP0656906A1 (en) 1995-06-14
HU9403516D0 (en) 1995-02-28
WO1993025582A1 (en) 1993-12-23
NZ299958A (en) 2000-07-28
JP2003180346A (en) 2003-07-02
JPH07507557A (en) 1995-08-24
AU4328193A (en) 1994-01-04
DE69326347T2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
DE69429095D1 (en) HUMANIZED ANTIBODIES
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
NO982062L (en) Humanized antibodies to human gp39, compositions containing them, and therapeutic use thereof
ATE218387T1 (en) ANTIBODIES CLEANSE
NO942912L (en) Construction, cloning and expression of humanized monoclonal antibodies to human interleukin-5
UA29494C2 (en) Humanized antibodies, methods for producing thereof, a method for treatment of Crohns disease, a method for treatment OF disseminated sclerosis, pharmaceutical composition
DE60231651D1 (en) PROTEIN CLEANING PROCESS
DE69531679D1 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
RS20130234A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
ATE169031T1 (en) CELL RECEPTOR SPECIFIC MONOCLONAL ANTIBODIES AGAINST STEM CELL FACTOR RECEPTOR
ATE222928T1 (en) HUMANIZED ANTIBODIES AGAINST CD38
Baughn et al. Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis.
KR950700779A (en) Protein purification method
GR3036906T3 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof.
ATE132197T1 (en) MONOCLONAL ANTIBODIES
ATE142789T1 (en) CARRIER FOR BINDING ANTIPHOSPHOLIPIDE ANTIBODIES, IMMUNO TEST USING THESE ANTIBODIES AND KIT THEREOF
ATE248190T1 (en) LYMPHOCYTE CHEMOATTRACTION TRIGGERING FACTOR AND USES THEREOF
FI20095269A (en) Human endothelial cell molecule affecting the binding of lymphocytes
DE69426767D1 (en) Anti idiotypic antibodies to gonococci and methods and compositions using them.
ES2054484T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIGEN-ANTIBODY COMPLEXES, AS WELL AS THE USE OF THE SAME.
DK0493446T3 (en) Treatment of autoimmune disease.
NO972522L (en) Monoclonal antibodies with immunosuppressive activity
FR2571146B1 (en) CARCINO-FETAL ANTIGENS OF HUMAN PANCREAS AND A PURIFICATION PROCESS, ANTISERUM AGAINST SUCH ANTIGENS AND ITS PREPARATION METHOD AND DIAGNOSTIC COMPOSITIONS CONTAINING THEM
DE3775182D1 (en) MONOCLONAL ANTIBODIES AGAINST HUMAN IGE RECEPTORS ON LYMPHOCYTES, THESE ANTIBODY-PRODUCING HYBRIDOMAS AND REACTION APPROACHES TO USE THESE ANTIBODIES.
DE69227918D1 (en) USE OF A CDw52-SPECIFIC ANTIBODY FOR THE TREATMENT OF JOINT IGNITIONS MEDIATED BY T-CELLS

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121176

Country of ref document: FI

MA Patent expired